We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where ...

Janelle Zeihen worried she'd have to file for bankruptcy after learning she owed $250,000 for her Crohn's disease treatment.

AbbVie generated $56 billion in revenue, achieving an operating profit of $12 billion and a net income of $4.3 billion, ...

AbbVie ABBV is set to report first-quarter 2025 earnings on April 25, before the opening bell. The Zacks Consensus Estimate ...

Passive income is essential in retirement, but building a dependable stream isn't easy. Fortunately, top-tier dividend stocks ...

AbbVie may be setting its sights on 2026, but analysts are already smitten with its present-day promise. Cantor Fitzgerald ...

Paul Stoffels left his perch as J&J’s chief scientific officer in 2022 to replace Galapagos’ founding CEO Onno van de Stolpe, ...

Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major ...

Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth ...

Galapagos (Euronext: GLPG) has appointed Henry Gosebruch as chief executive of its upcoming oncology spin-off, marking a ...

The first quarter of 2025 will be remembered for rapid change. U.S. presidential transitions typically focus on achieving one ...

Not only are pharmaceutical stocks excellent defensive investments, some pharma stocks pay sizable dividends that can be a ...